JAZZ PHARMACEUTICALS, INC.
SAN JOSE, DE

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) is an international biopharmaceutical company focused on improving patients’ lives by identifying, developing, and commercializing meaningful products that address unmet medical needs. We have a diverse portfolio of products and product candidates, with a focus in the areas of sleep and hematology/oncology. We also support commercial products in other therapeutic areas where we can meaningfully address serious medical needs. As part of our unwavering commitment to improve patients’ lives, we are continuing to expand our commercial product portfolio and our research and development pipeline in therapeutic areas that can leverage our unique expertise. We do this through a growth strategy of growing sales of the existing medicines in our portfolio; acquiring commercial products or product candidates that are in late-stage development; and pursuing focused development of our pipeline of differentiated therapies. Everything we do at Jazz Pharmaceuticals is focused on three things: putting patients first, being a great place to work, and living our shared values. OUR PRODUCTS Our therapeutic areas of focus include sleep and hematology/oncology – areas in which we have a deep understanding of the patient journey and a suite of products and product candidates to address critical needs. Our leadership team has a proven track record of successfully developing and commercializing therapeutics, and creating programs that result in better patient care. They’ve also driven shareholder value, and built Jazz Pharmaceuticals into an employer of choice. Bruce C. Cozadd co-founded Jazz Pharmaceuticals, Inc. in 2003 and has served as our Chairman and Chief Executive Officer since April 2009. From 1991 until 2001, he held various positions with ALZA Corporation, a pharmaceutical company acquired by Johnson & Johnson, most recently as Executive Vice President and Chief Operating Officer, with responsibility for research and development, manufacturing and sales and marketing. Previously at ALZA Corporation he held the roles of Chief Financial Officer and Vice President, Corporate Planning and Analysis. Mr. Cozadd serves on the boards of two non-profit organizations, The Nueva School and SFJAZZ. He received a B.S. from Yale University and an M.B.A. from the Stanford Graduate School of Business. Suzanne Sawochka Hooper was appointed our Executive Vice President and General Counsel as of March 2012. From 1999 through early 2012, she was a partner in the law firm Cooley LLP. Ms. Hooper served for several years as a member of Cooley’s Management Committee and as Vice Chair of the firm’s Business Department. While at Cooley, Ms. Hooper practiced corporate and securities law, primarily with companies and investors in the life sciences industry. Ms. Hooper received a J.D. from the University of California, Berkeley, Boalt Hall School of Law and a B.A. in Political Science from the University of California, Santa Barbara. Ms. Hooper is a member of the State Bar of California. Heather McGaughey was appointed Senior Vice President of Human Resources in March 2012. From 2008 to 2012 she served as Jazz’s Vice President of Human Resources. In 2007, she served as Managing Director, Private Equity Services at Craford Benefit Consultants, a human capital and benefit consulting firm. From 1998 to 2006 Ms. McGaughey served at CNET Networks, Inc., a global interactive media company, most recently as Senior Vice President, Human Resources. Previously, she held various positions of increasing responsibility in the Human Resources field at Time Inc. in New York and California, and at Manufacturers Hanover Trust, now a part of JP Morgan Chase. Ms. McGaughey received her B.A. from Smith College. She serves on the Board of California Strategic Human Resources Partnership (CSHRP) and the Advisory Board of the Biotech Organization Learning and Development (BOLD) Group. Senior Vice President, Jazz Pharmaceuticals Europe and Rest of World Iain McGill was appointed our Senior Vice President, Jazz Pharmaceuticals Europe and Rest of World as of March 2015. He served as Head of EUSA International and Senior Vice President, Jazz Pharmaceuticals from March 2014 to March 2015 and our Chief Commercial Officer, EUSA Pharma, from June 2012, when he joined Jazz Pharmaceuticals in connection with the EUSA Acquisition. From October 2011 until he joined Jazz Pharmaceuticals, Mr. McGill served as Chief Commercial Officer at EUSA Pharma (Europe) Ltd., where he previously served from August 2010 to September 2011 as President Europe, International & Global Marketing and from January 2010 to July 2010 as President of Europe. From 2006 to 2009, Mr. McGill served as Vice President and Global Business Manager at Wyeth, a pharmaceutical company acquired by Pfizer Inc. In 2016, he joined the board of directors and audit committee of Otonomy Inc., a biopharmaceutical company. Mr. McGill began his pharmaceutical career in sales and over 20 years held various positions in sales management, market research, marketing, business development and general management at Syntex Corporation (acquired by Roche Holding Ltd.), Roche Holding Ltd. and Novartis AG. Mr. McGill received a B.Sc in Biochemistry from the University of London. Robert McKague joined Jazz Pharmaceuticals in October 2011. From 2010 to 2011, he served as Senior Counsel for Actelion Pharmaceuticals, Inc., where he provided compliance and legal guidance for all commercial departments. In 2009 and 2010, Mr. McKague served as Senior Corporate Counsel, Litigation for Oracle America. He was our Senior Corporate Counsel from 2006 to 2009, responsible for ensuring compliance with federal and state regulations for promotion and marketing. Prior to 2006, he held positions with Morrison & Foerster LLP and the Board of Governors of the Federal Reserve System. Mr. McKague received his J.D. from the University of California Hastings College of Law and his B.S. in International Relations and French from San Francisco State University.